This report studies the global High Potency API /HPAPI market, analyzes & researches the High Potency API /HPAPI development status and forecast in United States, EU, Japan, China, India and Southeast Asia.
The high prevalence of liver-related diseases has coaxed several industry players and research institutes to invest in development of sophisticated NASH diagnostic and therapeutic products. Owing to these reasons, the global NASH biomarkers is expected to reach a valuation of US$1.7 bn by the end of 2024 from US$201.2 mn in 2016.
During the forecast period of 2016 and 2024, the global market is estimated to progress at a CAGR of 31.7%.
In terms of geography, the global NASH biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
The report states that Europe will continue to dominate the global market due to the increasing pool of population suffering from NAFLD and NASH.
This report studies the global High Potency API /HPAPI market, analyzes and researches the High Potency API /HPAPI development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
F. Hoffmann-La Roche
Eli Lilly and Company
Teva Pharmaceutical Industries
Merck & Co.
Category: Market Research Publishers and RetailersCompany profile: Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns. Our online stage, KMInsights.com, offers an unmatched gathering of market examination reports, organization audits, databooks, articles, periodical distributions, databases, on-line endorser administrations, and a great deal m ...
For more information:Make an Inquiry about this report HERE!